Nomexor (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. At the same time, it stimulates nitric‑oxide release from the endothelium, causing blood vessels to relax. The combined actions reduce cardiac output and peripheral resistance, leading to lower blood pressure.

The appropriate dose of Nomexor is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any co‑existing health issues. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will provide specific instructions.

Safety data for nebivolol in pregnancy and lactation are limited, and the drug is generally not recommended unless the potential benefit justifies the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Nomexor product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Nebivolol is a third‑generation, β1‑selective blocker that also promotes nitric‑oxide‑mediated vasodilation, which can improve endothelial function. Compared with older non‑selective beta‑blockers, it may cause fewer metabolic side effects and offers additional vasodilatory benefits, making it a preferred option for some patients with hypertension and heart failure.

Nomexor tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Nomexor is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, marked hypotension, atrioventricular block, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, difficulty breathing, or swelling of the face or throat.

Nomexor is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals with uncompensated heart failure. Caution is also advised for patients with asthma, severe liver disease, or uncontrolled diabetes.